Oncology
Advanced oncology biomarker and bioanalytical services designed to accelerate oncology and immuno-oncology therapeutic development.
Deep Expertise in Developing Oncology Therapeutics
Cancer remains one of the most complex and challenging diseases to treat and is a leading cause of death globally. Advances in immuno-oncology and immune system research are transforming treatment strategies and creating new opportunities for therapeutic innovation.
Synexa combines deep expertise in immunology and oncology bioanalysis with validated analytical platforms to support the development of next-generation cancer therapies. We deliver high-quality, clinically relevant data to answer complex scientific questions and accelerate oncology drug development.
Immuno-oncology
The rise of immuno-oncology therapies, including CAR‑T cell therapies, therapeutic vaccines, tumour-targeting monoclonal antibodies, oncolytic viruses and immune checkpoint inhibitors, has revolutionised cancer treatment.
However, the complex interplay between the immune system and tumours requires comprehensive bioanalytical strategies to monitor treatment response, assess efficacy and understand mechanisms of action.
Oncology
A deep understanding of cancer biology and validated biomarkers is critical for successful therapeutic development. Synexa’s oncology biomarker services support programmes from translational research through to Phase III clinical trials.
Our integrated approach enables:
- Insight into disease mechanisms
- Monitoring of disease progression
- Accurate assessment of therapeutic efficacy
- Prediction of patient outcomes
Oncology Bioanalytical Services Across Clinical Development
We offer a complementary suite of bioanalytical services specifically tailored for oncology studies from translational studies up to phase III trials.
Flow Cytometry for Oncology Research
Single cell analytical technologies such as multicolor flow cytometry are critical in defining patient immunological profiles, guiding treatment decisions and enabling the characterisation of the immune system. Synexa's expert team has extensive experience in designing robust assays to answer critical questions in the field of oncology.
Applications include: Functional assays, cytokine release assays, potency assays (cytotoxicity and ADCC), immunophenotyping, cell therapy persistence and potency, CAR T cell characterisation and immunogenicity, cell proliferation, activation, exhaustion and apoptosis, immune checkpoint analysis, rare cell detection.
Translational Oncology Research
Synexa offers a human in vitro translational research platform that focuses on addressing immunobiological questions related to drug target engagement and expression of pharmacology.
Translational studies provide an innovative platform for oncology research, leveraging patient samples and innovative analytical technologies to unlock critical insights. Our tailored approach, combining genetic assessments, biomarker analysis and expert consultation empowers the furtherment of oncology therapeutic research.
Biomarker Analysis and Immunoassays
Synexa has extensive experience in designing bespoke biomarker panels for multiplexed immunoassays. The MSD platform offers absolute quantification of proteins in several matrices. Where sample availability is limited, we harness the Olink platform which requires only 1µL of sample and can analyse up to 92 different markers. Immuno-oncology and oncology specific panels are available or can be customised to your specific needs.
Assays include: drug-drug interaction, drug pharmacokinetics, drug metabolism, drug immunogenicity, dose response, safety and efficacy.
Tissue Imaging and Tumour Microenvironment Analysis
Synexa's Tissue and Cell Imaging Services interrogate multiple targets in situ covering a wide range of applications, from multiplex immunofluorescent tissue imaging to single molecule analysis in individual cells.
We employ a synergistic approach that integrates traditional hematoxylin and eosin staining techniques with customisable multi-plex (4 and 8 plex) immunofluorescence panels (mIF). Oncology specific panels for spatial analysis of the tumour microenvironment investigate immune cell infiltration patterns, tumour-immune cell crosstalk, tumour progression, immune exhaustion and response to immunotherapies.
Genomics and Transcriptomics in Oncology
Synexa's genomic and transcriptomic approaches offer a deep understanding of cancer biology and allows investigation into immunotherapy response, monitoring disease biomarkers, evaluating mechanisms of resistance and tracking cell and gene therapy treatments in clinical trials. We make use of dPCR and the Nanostring platform which have curated immuno-oncology specific panels including the PanCancer IO 360 panel.
Applications include: Monitoring of cell and gene therapy persistence, cellular kinetics and biodistribution in tissue, specific gene expression, ctDNA monitoring, viral vector genome titre measurement, vector copy number determination, somatic mutation detection, chimerism analysis, biomarker verification, checkpoint marker expression and quantification of CAR transgene integration.
More on Oncology
What are Immune Checkpoint Inhibitors?
Liquid biopsies: a non-invasive picture of cancer physiology
Uncovering tissue complexity through spatial biology
World Cancer Day 2024: Closing the gap
Bridging the Gap: Translating Animal Model Findings to Clinical Oncology Breakthroughs
Patient Derived Organoids: Shaping the Fight Against Paediatric Brain Cancer
A controlled detonation: Targeted antibody drug conjugates (ADCs) for oncology
A controlled detonation: Targeted antibody drug conjugates (ADCs) for oncology
Patient Derived Organoids: Shaping the Fight Against Paediatric Brain Cancer
Bridging the Gap: Translating Animal Model Findings to Clinical Oncology Breakthroughs
Improving the quality of human health
Contact us
Discuss biomarker and bioanalytical solutions to accelerate your therapeutic pipeline
